Attached files

file filename
EX-32.1 - EX-32.1 - F-star Therapeutics, Inc.sbph-ex321_11.htm
EX-31.2 - EX-31.2 - F-star Therapeutics, Inc.sbph-ex312_6.htm
EX-31.1 - EX-31.1 - F-star Therapeutics, Inc.sbph-ex311_7.htm
EX-21.1 - EX-21.1 - F-star Therapeutics, Inc.sbph-ex211_242.htm
EX-4.5 - EX-4.5 - F-star Therapeutics, Inc.sbph-ex45_479.htm
10-K - 10-K - F-star Therapeutics, Inc.sbph-10k_20191231.htm

Exhibit 23.1



Consent of Independent Registered Public Accounting Firm


We consent to the incorporation by reference in the Registration Statement (Nos. 333-215122, 333-218399 and 333-234436) on Form S-3 and Registration Statement (Nos. 333-212047, 333-226508) on Form S-8 of Spring Bank Pharmaceuticals, Inc. of our report dated February 14, 2020, relating to the consolidated financial statements of Spring Bank Pharmaceuticals, Inc. and its subsidiaries, appearing in this Annual Report on Form 10-K of Spring Bank Pharmaceuticals, Inc. for the year ended December 31, 2019.




Boston, Massachusetts

February 14, 2020